• Categories
  • Archives

Brazil Approves New Antiblindness Treatment

Eyetech Pharmaceuticals announced yesterday approval of Macugen in Brazil for the Treatment of Neovascular Age-Related Macular Degeneration.

The therapy is being presented as the first treatment that helps preserve vision in all subtypes of neovascular AMD by slowing vision loss.


The approval for Macugen was granted by Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária).


The therapy was approved in the United States in December 2004 and in Canada in May 2005.  Eyetech and Pfizer Inc co-promote Macugen in the U.S. 


Eyetech has granted Pfizer the exclusive rights to commercialize Macugen in countries outside the U.S., including Brazil, pursuant to a royalty-bearing licensing agreement.


Macugen is the first in a new class of ophthalmic drugs to specifically target vascular endothelial growth factor (VEGF), a protein that acts as a signal in triggering the abnormal blood vessel growth and leakage that is the hallmark of neovascular AMD.


Macugen specifically binds to VEGF 165, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes thought to be responsible for the vision loss associated with neovascular AMD.  Thus, Macugen helps preserve vision by slowing vision loss.


Neovascular AMD is the leading cause of irreversible severe vision loss in patients older than 60 years of age in developed countries.  More than 500,000 people worldwide lose their sight annually from the disease. 


In Brazil, nearly 7 million people live with some form of AMD and more than 135,000 new cases are reported each year, with the incidence likely to increase significantly with a growing aging population.


Macugen is administered in a 0.3 mg dose once every six weeks by intravitreal injection.  It is expected to be available in the Brazilian market later this year.  Macugen has also been filed for approval in the European Union, Australia and Switzerland.


About Macugen


Macugen is indicated in the United States for the treatment of neovascular age-related macular degeneration, and in Canada for subfoveal choroidal neovascularization (CNV) secondary to neovascular AMD. 


Macugen is a pegylated anti-VEGF aptamer, which binds to vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the pathological processes that contribute to the vision loss associated with neovascular AMD.


Safety Information


Macugen is contraindicated in patients with ocular or periocular infections.


Intravitreal injections including those with Macugen have been associated with endophthalmitis.  Proper aseptic injection technique – which includes use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent) – should always be utilized when administering Macugen. 


In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.


Increases in intraocular pressure (IOP) have been seen within 30 minutes of injection with Macugen. Therefore, IOP as well as the perfusion of the optic nerve head should be monitored and managed appropriately.


Serious adverse events related to the injection procedure occurring in less than 1% of intravitreal injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.


Most frequently reported adverse events in patients treated for up to 2 years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased IOP, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities.  These events occurred in approximately 10% to 40% of patients.


Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. 


Eyetech’s initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular AMD.  Macugen is also being studied for other indications including diabetic macular edema and retinal vein occlusion.


Eyetech Pharmaceuticals, Inc. – www.eyetk.com


Macugen – www.macugen.com


PRNewswire

Tags:

  • Show Comments (3)

  • LUIZ EUFRASIO RIBEIRO FILHO

    MACUGEN NO TRATAMENTO DA DEGENERAÀƒ‡AO MACULAR RELACIONADO A IDADE
    SOU OFTALMOLGISTA EM SÀƒƒO LUIS DO MARANHÀƒƒO=BRASIL. E GOSTARIA DE UTILIZAR O MACUGEN EM PACIENTES COM DEGENERAÀƒ‡AO MACULAR RELACIONADO A IDADE. QUERO TER AS INFORMAÀƒ‡OES SOBRE O PRODUTO, TAIS COMO, PREÀƒ‡O, DOSAGEM INTRAVITREA, PERIODO DE APLICAÀƒ‡OES ,ETC…..E COMO POSSO ADQUIRÀƒÂ-LO.

  • Guest

    gabymax@free.fr
    Is MACUGEN TREATMENT AVAILABLE IN SWITZERLAND ?

  • Guest

    maculopatia humeda
    hola, vivo en uruguay necesito saber donde aplican macugen en america (brasil or argentina), donde consigo macugen, a cuanto se vende, mi madre tiene 72 a˱os y ha perdido un ojo.
    I LIVE IN URUGUAY I NEED TO KNOW WHERE APLLICAT MACUGEN IN SUD AMERICA (BRAZIL OR ARGENTINA) WHERE I CAN BUY, COSTELLE, PRICE, MY MOTHER 72 EARS OLD AND SHE CANT SEE
    PLEASE SEND lvalassi@antel.com.uy thanks

Your email address will not be published. Required fields are marked *

comment *

  • name *

  • email *

  • website *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Ads

You May Also Like

Brazil Gets Chile Backing for UN Security Council

In an interview after the meeting with Brazilian President Luiz Inácio Lula da Silva, ...

Brazil Wants Portugal Help in Mercosur-EU Free Trade Agreement

In Porto, Portugal, today, Brazilian President Luiz Inácio Lula da Silva asked for Portuguese ...

After US and Germany, Portugal Gets Brazil’s Distribution Center

The Brazilian Minister of Development, Industry and Foreign Trade, Luiz Fernando Furlan, inaugurates tomorrow, ...

Brazil’s Primary Surplus Grows to 6.22% of GDP

The primary surplus, the economy that the Brazilian government makes to pay the interest ...

Brazil: 2 Million in Rio Beach to Ring In the New Year

Hotels along the beaches of the Southern Zone of Rio are practically full for ...

Brazil Presents the World in Europe Today Its Ethanol Success Story

Sugarcane and global warming. What do they have to do with each other? Everything, ...

Brazil’s Thor Has 20 Mines to Supply Overseas Marble Market

Brazilian company Thor Granitos main aim for 2009 is to guarantee the maintenance of ...

Brazil’s Projection to Grow Falls for the 11th Time in a Row, Now to a Mere 0.81%

The projection of financial institutions for the Brazilian economic growth, this year, has been ...

In Brazil, the Sarneys Are Synonym with Mismanagement and Corruption

When back in September 2003, the Getúlio Vargas Foundation shocked Brazil by placing Maranhão ...

Elin, Swedish Voice & Brazilian Soul

This versatile multilingual vocalist was born in Sweden, but you would never know it ...